tetano
Editor, Senior Moderator
Mol Ther Methods Clin Dev. 2017 Sep 20;7:74-82. doi: 10.1016/j.omtm.2017.09.003. eCollection 2017 Dec 15.
[h=1]In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections.[/h] Andrews CD[SUP]1[/SUP], Luo Y[SUP]1[/SUP], Sun M[SUP]1[/SUP], Yu J[SUP]1[/SUP], Goff AJ[SUP]2[/SUP], Glass PJ[SUP]2[/SUP], Padte NN[SUP]1[/SUP], Huang Y[SUP]1[/SUP], Ho DD[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Monoclonal antibodies (mAbs) have wide clinical utility, but global access is limited by high costs and impracticalities associated with repeated passive administration. Here, we describe an optimized electroporation-based DNA gene transfer platform technology that can be utilized for production of functional mAbs in vivo, with the potential to reduce costs and administration burdens. We demonstrate that multiple mAbs can be simultaneously expressed at protective concentrations for a protracted period of time using DNA doses and electroporation conditions that are feasible clinically. The expressed mAbs could also protect mice against lethal influenza or Ebola virus challenges. Our findings suggest that this DNA gene transfer platform technology could be a game-changing advance that expands access to effective mAb therapeutics globally.
[h=4]KEYWORDS:[/h] DNA-based antibody gene transfer; Ebola; electroporation; infectious disease; influenza; plasmid
PMID: 29034261 PMCID: PMC5633264 DOI: 10.1016/j.omtm.2017.09.003
[h=1]In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections.[/h] Andrews CD[SUP]1[/SUP], Luo Y[SUP]1[/SUP], Sun M[SUP]1[/SUP], Yu J[SUP]1[/SUP], Goff AJ[SUP]2[/SUP], Glass PJ[SUP]2[/SUP], Padte NN[SUP]1[/SUP], Huang Y[SUP]1[/SUP], Ho DD[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Monoclonal antibodies (mAbs) have wide clinical utility, but global access is limited by high costs and impracticalities associated with repeated passive administration. Here, we describe an optimized electroporation-based DNA gene transfer platform technology that can be utilized for production of functional mAbs in vivo, with the potential to reduce costs and administration burdens. We demonstrate that multiple mAbs can be simultaneously expressed at protective concentrations for a protracted period of time using DNA doses and electroporation conditions that are feasible clinically. The expressed mAbs could also protect mice against lethal influenza or Ebola virus challenges. Our findings suggest that this DNA gene transfer platform technology could be a game-changing advance that expands access to effective mAb therapeutics globally.
[h=4]KEYWORDS:[/h] DNA-based antibody gene transfer; Ebola; electroporation; infectious disease; influenza; plasmid
PMID: 29034261 PMCID: PMC5633264 DOI: 10.1016/j.omtm.2017.09.003